Form D · Biotechnology
Perceive Biotherapeutics, Inc.
South San Francisco, CA · CIK 0001962036
Offering snapshot reported Jan 13, 2023 · SEC filing
- Reported sold
- $40M Offering amount: $78M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 13, 2023 | Initial | $39,999,986 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-470703
Source: Form D, filed Jan 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Watson Debi | Director |
| Robert Jackson | Director |
| Kirsten Angela Macfarlane | Director, Executive, Promoter |
| Randall Olson | Director |
| Anne Rubin | Director, Executive |
| Cameron Wheeler | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6000 Shoreline Drive, Suite 206 Attn: Ceo
South San Francisco, CA, 94080
South San Francisco, CA, 94080